MedTrace Logo

Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects

NCT05938452 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-16

No results posted yet for this study

Summary

This study is designed to assess the safety and PK/PD of GTB and Benzoic Acid (Benzoate) using a single ascending dose (SAD) study (under fasting conditions).

Conditions

  • Neurological Disorder

Interventions

DRUG

Glyceryl Tribenzoate

Oral Solution

Sponsors & Collaborators

  • Liberyx Therapeutics Ltd.

    collaborator UNKNOWN

  • Forest Hills Lab

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-12
Primary Completion
2023-10-19
Completion
2023-10-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05938452 on ClinicalTrials.gov